ZymeworksInc (NYSE: ZYME): The Current Market Standing Of The Stocks
Looking for a company to invest in? Zymeworks Inc. can be a good candidate. Though running a bit slow, this company has shown some great leaps and bounds in the last quarter. NYSE: ZYME is a great option for buyers, but to know more read further.
About Zymeworks Inc.
Found in 2003 and headquartered in Vancouver, Canada, Zymeworks Inc. is a biopharmaceutical company. They are targeted towards the development of multispeciality treatment; their treatment is mostly for treating inflammatory diseases, cancer, and autoimmune disease. They have a protein engineering molecular development program that helps in creating new treatments. Azymetric and EFFECT are two such software.
Currently, the market performance of Zymeworks Inc. is not the most steady and stout. Many groups have recently decreased their price target of the NYSE: ZYME at https://www.webull.com/quote/nyse-zyme. Last week, Zymeworks Inc. stock fell by 5.9%. Hiwvrere, when the day to day trading is observed, there is a growth in the share volume, as there was a 147% growth in volume. Analysts are much divided when it comes to these stocks. Some have given the stock a buy rate, some have given a strong rate, and sone have given hold rating.
The quick ratio and current ration of the company are at 6.92 and debt to equity is at 0.01. Also, the 200-day moving average is at $39.35 and a 5-day moving average is at $36.85. The beta of the company is at 1.15 and PE ration is at -9.22. Their earnings were last announced in May 2020. The EPS was 0.64 and the return on equity and net margin were -46.17% and 629.37%. Also, the revenue of $8.27 million was above the estimated revenue of $7. 78 million.
Position of hedge funds
Many hedge funds also have changed and updated their position with the Zymeworks Inc. stocks. Most of them have raised their stakes in the first quarter. Some of those hedge funds are steward partners investment advisory LLC (28.1% increase), Rockefeller capital management LP (20.8% increase), Chartwell investment partners LLC (14.4% increase), Alps advisors Inc (1.6% increase), etc.
Zymeworks Inc. and Merck
Only recently it was announced by both the companies that Merck will be working in partnership with Zymeworks Inc. The former will be working on various candidates fro advanced multispecific antibody therapies. Merck will be using the EFECT and Zymeworks azymetric platforms to develop these therapies. This agreement is to provide Merck with complete research and development facilities for creating and commercializing three antibody candidates. Both Azymetric and EFECT platforms are for developing engineered antibodies towards various targets.
Zymeworks Inc. is a company that requires a lot of studies before one starts investing in the stocks. Being a biopharmaceutical company, it does have the edge to be in a growing industry. But there is still a lot of research to do before one leaps forward. You can buy stocks online after checking more stock news. Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.